In an un­usu­al move, ICER re­scinds draft re­port on JAK drugs for rheuma­toid arthri­tis to re­vise its mod­el­ing ap­proach

Two years ago, the In­sti­tute for Clin­i­cal and Eco­nom­ic Re­view (ICER) ad­mon­ished Ab­b­Vie for over­pric­ing the best-sell­ing drug in the world — Hu­mi­ra — along with the raft of ri­val drugs ap­proved for rheuma­toid arthri­tis. On Wednes­day, the in­flu­en­tial cost-ef­fec­tive­ness watch­dog re­scind­ed its draft re­port on the new crop of JAK in­hibitors, say­ing it was re­vis­it­ing the mod­el­ing ap­proach it em­ployed in the analy­sis pub­lished in late Sep­tem­ber.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN